The final conversation of Episode 16 explores possible possible pathways and treatment strategies for NASH therapy in a future world with multiple classes of agents.
In different ways, Mazen Noureddin and each Surfer discuss how cost-effective patient treatment might actually provide the right medicine for the right patient all along the therapeutic path.
What makes NASH a little different from other diseases? Because the liver can heal itself, doctors will need to manage drug use during the disease regression process if all goes well.
This is a different way of thinking, driven in part by the ground-breaking cost-effectiveness work Mazen and others have brought forward.